At Creative Biolabs, scientists are dedicated to bringing together years of valuable experience to help our clients shorten the research journey. We are committed to providing an integrated solution for CD138 assay services and are dedicated to reducing the overall project development timeline for our clients.
CD138, also known as Syndecan-1, is a member of the syndecan family involved in cell-cell and cell-matrix interactions. As a cell surface protein, CD138 is composed of three structural domains: a cytoplasmic domain, a transmembrane domain, and an extracellular domain. Which extracellular domain could bind heparin sulfates and chondroitin sulfates. CD138 is highly expressed on differentiated plasma cells (PC) and various epithelial cell types, and plays an important role in the cell proliferation, migration, and organization of the cytoskeleton.
CD138 is involved in carcinogenesis, particularly cell proliferation, angiogenesis, and tumor invasion and metastasis. Abnormal expression of CD138 is associated with a variety of malignant tumors. For example, CD138 overexpression has been reported in breast, pancreatic, ovarian, endometrial, and prostate cancer. However, in other types of cancer (such as lung, gastric, renal, and colorectal cancer), CD138 expression is reduced compared to adjacent normal epithelium.
Fig.1 Schematic illustration of Syndecan family. (Szatmári, 2013)
Because of its association with carcinogenic processes, therapy strategies targeting CD138 provide promise for several tumors, such as multiple myeloma (MM). To date, several approaches including antibodies, ADCs, immune-cytokines, and CAR-T therapies have developed for the treatment of MM. For example, indatuximab ravtansine (BT062) is an anti-CD138 mAb drug conjugate (ADC) specifically delivering a cytotoxic maytansine derivative to MM cells for targeted clearance of tumor cells.
Fig.2 Mechanism of action of antibody-drug conjugates (ADC). (Bruins, 2020)
Creative Biolabs is specialized in providing custom tumor marker assay services to both academia and biotech/pharmaceutical industries, we are committed to designing comprehensive CD138 assay portfolio services, covering the initial target validation to the later preclinical analysis to accelerate the research process.
For more details of our CD138 assay portfolio services, please don’t hesitate to contact us for more information.
References
For Research Use Only | Not For Clinical Use
Download our brochure